Mark Arnold Hagler
CIK: 0002126029
Transaction Breakdown
Open Market Buys (P)1 (50.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NBP
NovaBridge Biosciences
Officer
Discretionary Trading P&L
Holdings
About Hagler Mark Arnold
Hagler Mark Arnold (SEC CIK 0002126029) files insider reports with the SEC as Chief Commercial Officer of NovaBridge Biosciences (NBP).
Signal8 holds 3 ownership filings by Hagler Mark Arnold (1 Form 3, 2 Form 4), filed between Apr 22, 2026 and Jul 10, 2026. Those filings report 2 transactions, from Apr 24, 2026 to Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hagler Mark Arnold's filings is in ROCKVILLE, MD.
Recent filings by Hagler Mark Arnold
Other insiders filing for NovaBridge Biosciences (NBP)
- Silberstein Charles, Chief Financial Officer
- Woo Ian Ying, Director
- Dennis Phillip Andrew, Chief Medical Officer
- Cao Sean Wuxiong, Chief Bus. Development Officer
- Dewhurst Martin William, Director
- Xu Cong Claire, EVP, Clinical Development